Latest Recruitment News

Hiremii Group has successfully raised $650,000 through an oversubscribed placement, underscoring strong investor confidence as it pushes forward with commercialising its AI-driven recruitment platform.

Prescient Therapeutics has bolstered its cash reserves to $12.3 million following a $9.8 million capital raise, while progressing its PTX-100 cancer therapy through global Phase 2 trials with encouraging early lymphoma results.

Lithium Universe has bolstered its photovoltaic recycling program by appointing a robotics expert to accelerate silver recovery technology, advancing plans for a Texas recycling facility.

EDU Holdings reports a remarkable 82% increase in total student enrolments at its Ikon Institute for Trimester 3, 2025, driven by strong demand and new course offerings amid evolving regulatory conditions.

Stakk Limited has successfully raised $15 million through an oversubscribed equity placement, underscoring strong institutional confidence in its Embedded Finance growth strategy. The funds will accelerate expansion in the U.S. and Australian markets as the company’s recurring revenue surges.

Kelsian Group has postponed the start of its new Kangaroo Island ferry service to June 2026, citing vessel delivery delays and aiming to avoid peak season disruptions. The new ferries will significantly increase capacity and offer fare discounts to residents during the transition.

ARN Media announces a significant leadership change as CEO Ciaran Davis steps down after 16 years, with COO Michael Stephenson set to take the helm in January 2026.

Savannah Goldfields is on track to resume gold production at its Georgetown Gold Project by the end of October, with key maintenance and environmental approvals completed.

Paradigm Biopharmaceuticals has dosed participants in its pivotal Phase 3 trial for knee osteoarthritis across the US and Australia, progressing steadily towards a mid-2026 interim analysis.

Dimerix Limited’s lead drug candidate DMX-200 has been granted Orphan Drug Designation in Japan for treating Focal Segmental Glomerulosclerosis (FSGS), enhancing its regulatory and commercial prospects in a key market.

Lindian Resources has adopted an owner-operator mining model at its Kangankunde Rare Earths Project, aiming to reduce mining costs by around 30% and accelerate production start to early 2026.

Race Oncology has secured Investigational New Drug approval from South Korea’s regulatory authority, enabling Phase 1 clinical trials of RC220 in combination with doxorubicin for solid tumour patients across four Korean sites.